TriangleCIML NK cells for AML (NCT06152809)
CIML NK cells for AML trial for Acute Myeloid Leukemia (NCT06152809). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia in which a small amount of disease remains after treatment, called measurable residual disease.
The idea: combine two treatments. Natural killer cells from a donor are trained in the lab with cytokines to become memory-like, and infused after lymphodepleting chemotherapy, with interleukin-2 injections. Venetoclax, a pill approved for this leukemia that blocks a protein called BCL-2, is taken alongside.
This is the first time the combination will be given to people. About 10 participants will be treated, with a hospital stay of up to four weeks. At Dana-Farber in Boston, Evan Chen leads this safety study.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.